Intercept Pharmaceuticals Inc (ICPT)
28.94
+0.18 +0.63%
NASDAQ
Oct 29, 20:00
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 283.35M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -10.36 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -339.26M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 97.57% |
| Profit Margin (Quarterly) | -81.92% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0.00% |
| Price and Valuation | |
| Market Cap | 954.46M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 3.346 |
| PE Ratio | -- |
| Price to Book Value | -- |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | -6.930 |
| Free Cash Flow (Quarterly) | -15.07M |
| Return on Equity | Upgrade |
View All ICPT News
News
-
WireHeadlineTime (ET)
-
PR Newswire10/29 22:39
-
Yahoo10/29 13:00
-
Yahoo10/29 11:00
-
Globe Newswire10/29 08:00
-
Yahoo10/28 20:49
-
Yahoo10/28 19:45
-
Yahoo10/28 12:55
-
Yahoo10/23 21:50
-
Globe Newswire10/23 19:00
-
MT Newswires10/23 13:12
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 11/05/2020 08:30 EST | Misc | Intercept Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2020 |
| 11/05/2020 | Earnings | Intercept Pharmaceuticals Inc Third Quarter Earnings for 2020 Release |
| 08/10/2020 08:30 EDT | Misc | Intercept Pharmaceuticals Inc Second Quarter Earnings Conference Call for 2020 |
| 08/10/2020 | Earnings | Intercept Pharmaceuticals Inc Second Quarter Earnings Result for 2020 |
| 05/28/2020 10:00 EDT | Misc | Intercept Pharmaceuticals Inc Annual General Meeting for 2019 |
| 05/11/2020 08:30 EDT | Misc | Intercept Pharmaceuticals Inc First Quarter Earnings Conference Call for 2020 |
| 05/11/2020 | Earnings | Intercept Pharmaceuticals Inc First Quarter Earnings Result for 2020 |
| 02/25/2020 08:30 EST | Misc | Intercept Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 2019 |
| 02/25/2020 | Earnings | Intercept Pharmaceuticals Inc Fourth Quarter Earnings in 2019 Release |
| 02/25/2020 | Misc | Intercept Pharmaceuticals Inc Annual Report for 2019 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: https://www.interceptpharma.com
- Investor Relations URL: http://ir.interceptpharma.com/index.cfm
- HQ State/Province: New York
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Growth
- Next Earnings Release: Nov. 05, 2020
- Last Earnings Release: Aug. 10, 2020
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 28.94 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| CIG4926 | CI Global Health Sciences Corp Cl Y | 5.45% |
| NEC213 | Next Edge Bio-Tech Plus A | 2.97% |
| F000013KMV | ST Healthcare Innovations 7 F CA | 0.92% |
| F000011FZR | ST Healthcare Innovations 6 CA | 0.71% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- ICPT Tweets Stocktwits
Advertisement
